Corcept Will Pursue Two Corlux Phase III Studies Despite Initial Negative Result
This article was originally published in The Pink Sheet Daily
Executive Summary
Mifepristone fails to show a benefit over placebo for treating psychotic major depression in the first of three trials.
You may also be interested in...
Corcept To Pursue High-Dose Corlux For Psychotic Major Depression After Third Phase III Misses Its Mark
Funding may be needed, as Corcept’s cash is only expected to last through end of the second quarter.
Corcept To Pursue High-Dose Corlux For Psychotic Major Depression After Third Phase III Misses Its Mark
Funding may be needed, as Corcept’s cash is only expected to last through end of the second quarter.
Corcept Beginning Mifepristone Pivotal Trials For Psychotic Depression
The first of two trials testing rapid and sustained relief of psychotic features, designed under special protocol assessment with FDA, will begin "immediately," Corcept says. Corlux is expected to share the same safety restrictions as Mifeprex (RU-486).